




GLOBAL LIVER INSTITUTE

Annual Report | 2021
Highlights & Spotlights



globalliver.org



GLOBAL LIVER INSTITUTE

Annual Report | 2021
Highlights & Spotlights



Donate Today!



*We put your
contribution to work!*

Highlights & Spotlights



Donna R. Cryer, JD

For far too many people, 2021, the first that the world experienced the entirety of 12 months of the year experiencing the syndemics of COVID-19, liver disease, and growing demonstration of the pervasiveness of health inequities, was a time of darkness. **It is the role of an advocacy organization to create light in the form of hope, information, and solutions** as well as to shine a light on those individuals, entities, and initiatives that do the same. Throughout the annual report we will share with you the highlights from Global Liver Institute's many accomplishments and recognitions and where we have used our expanding position and platforms to elevate others and give them the spotlight they deserve.

The most transformational change to the organization was **the formalization of the Liver Action Network (LAN)**, an affiliated network of community organizations, that created a grassroots presence for GLI across the United States and into Canada. The creation of the LAN demonstrated that *GLI values patient-centeredness, collaboration, integrity, inclusion, and results* resonated with advocates and advocacy leaders.

The forcefulness of GLI advocacy on issues that make a real difference in the lives of patients and families culminated in testimony by two GLI witnesses at the U.S. House of Representatives Subcommittee on Reforming the Organ Transplantation System. Organ Procurement Organization performance standards and accountability were proven to be an issue not just for a few advocates but for members of Congress of both parties and ultimately the Administration.

We understand that the biggest barrier to our advocacy and the effectiveness of any efforts in liver health is lack of awareness. Our elevated visibility benefits the entire field. From the growing viewership of GLI LIVE, our weekly thought leader talk show which celebrated its 1st anniversary, to launching the first Chronic Liver Disease Trend Report with one of our industry partners at the American College of Gastroenterology meeting, to receiving both the American Association for the Study



Light is to darkness what
love is to fear: in the
presence of the one,
the other disappears

of Liver Diseases Distinguished Service Advocacy Award and the Global Genes Champion of Hope Founders Award in the same week, we were able to put liver health advocacy in the spotlight like never before. Even more gratifying was to shine the spotlight on the first recipients of the Global Liver Institute Excellence in Health Equity award at our inaugural Leadership in Liver Health Luncheon as part of our #Octoberis4Livers Campaign.

Throughout 2021, Team GLI stayed focused on scaling to meet the evolving needs of the liver community - patients, health care providers, researchers, industry partners, and policymakers - with creativity, caring, and commitment.

Donna R. Cryer, JD
President & CEO
Global Liver Institute

Contents

05

Board of Directors & Staff

09

Office of the CEO

11

Special Initiatives of the Office of the CEO

Diversity, Equity, Belonging	11
Leadership in Liver Health Luncheon	13
COVID-19 Response	14

15

European Office

International NASH Day	16
Culinary Event	19
Nutristyle App	19

21

NASH Programs

NASH Council	21
NASH Programs Impact	23

25

Advanced Advocacy Academy

29

Liver Cancers Programs

Liver Cancers Council	29
#OctoberIs4Livers	30
Liver Central	31

33

Pediatric and Rare Liver Diseases Programs

Pediatric and Rare Liver Diseases Council	33
Inaugural Rare Liver Diseases Month & #RareAware Campaign	34

35

Liver Health Policy

Liver Action Network	39
NASH Externally-Led Patient-Focused Drug Development Meeting	40

41

Communications

Social media	42
GLI LIVE	45

46

2020 External Audit Results

47

Thought Leadership: CEO Speaking Engagements

51

Financial Overview

53

Appendix

Our Mission

To improve the lives of individuals and families impacted by liver disease through *promoting innovation, encouraging collaboration, and scaling optimal approaches to help eradicate liver diseases*

Our Vision

For liver health awareness to be universal and for liver disease to take its proper place on the global public health agenda consistent with its prevalence and impact

An estimated 1.5 billion persons have chronic liver disease worldwide¹

1. Clinical Gastroenterology and Hepatology, 2019

Board of Directors



Victor J. Reyes, MBA
Board Chair
 Managing Director, Human Capital,
 Deloitte Consulting LLP



Donna R. Cryer, JD
 President & Chief Executive Officer,
 Global Liver Institute



Lisa Boyette, MD, PHD
Board Treasurer
 Vice President of Medical Affairs,
 Recursion Pharmaceuticals



Brian Munroe
Board Secretary
 Vice President Government Affairs,
 Bausch Health Companies Inc.



Laurie Mobley
Board Development Co-Chair
 Senior Vice President,
 BRG Communications



Amy L. Wright, JD
Board Development
 Co-Chair Partner,
 Taft Stettinius & Hollister



Nicholas Austin, JD
 Principal Corporate Legal Counsel,
 Microsoft, Inc.



Dennis R. Cryer, MD, FAHA
 Chief Medical Officer,
 CryerHealth LLC



Gary Deverman, CFRE
 Vice President,
 NutriStyle



Ben Goodman
 Liaison for Legislative Policy
 & External Communication,
 Maine Dept. of Economic
 & Community Development



Monica H. Mcgurk, MBA
 Senior Vice President & Chief
 Global Growth Officer,
 Kellogg Company



**Lewis R. Roberts,
 MB, CHB, PHD**
 Professor of Medicine
 and Consultant,
 Division of Gastroenterology
 & Hepatology, Mayo Clinic



Amita Shukla, MBA
 Founder & CEO,
 VitaMita

2021 Staff



Donna R. Cryer, JD
 President & Chief
 Executive Officer



Larry Holden
 Chief of Operations



Dhanita Nair
 Deputy Chief
 of Operations



Ivy Ahmed
 Liver Cancers
 Program Director



Elisabeth Vogel
 Liver Cancers
 Program Coordinator



Livia Alimena
 EU Office Director
 IND Director



Giacomo Donnini
 EU Office Manager
 IND Manager



Andrew Scott
 Policy Director



Gina Bartes
 Advanced Advocacy
 Academy (A3)
 Program Director



Alexis Story
 Advanced Advocacy Academy (A3)
 Program Coordinator



Jeff McIntyre
 NASH Program Director



Catherine Evans
 NASH Program Manager



Robert Mitchell-Thain
 Pediatric and Rare Liver Diseases
 Program Director



Nicole Wells
 Pediatric and Rare Liver Diseases
 Program Manager



Dawn Hall
 Communications Director



Carrie Gelula
 Brand Director



Jill Gerber
 Communications Manager



Christine Maalouf
 Social Media Manager



Ainsley Amundson
 Operations Manager
 Executive Assistant to CEO



Leanna Christensen
 Operations Coordinator

Calendar Overview

January

President & CEO Donna R. Cryer moderated National Health Council CEO Affinity Group discussion on **insights from Pfizer on the COVID-19 vaccine rollout**

March

President & CEO Donna R. Cryer spoke at **SXSW**

May

President & CEO Donna R. Cryer testified at **House Oversight and Reform Committee** on Organ Procurement

Announced its **Liver Action Network (LAN)**, an affiliation model that provides a structure for the formulation of joint liver health policy and programmatic solutions

February

Inaugural Rare Liver Diseases Month
#RareAware campaign

April

Worked collaboratively with the liver advocacy community to urge **USPSTF** to include NASH in the conversation with type 2 diabetes screening and treatment

June

International NASH Day, June 10

Urged **FDA & CDC** to update their guidances and regulations to consider additional COVID-19 vaccine doses for immunocompromised individuals

July

First **staff retreat**

September

Annual **A3 Training Program**, September 21-23

November

Led the first **Externally Led-Patient Focused Drug Development Meeting** on NASH

December

Launched **Liver Central**, a hub for all things liver cancer

Released **U.S. NASH Action Plan Scorecard**

August

Worked collaboratively with the Liver Action Network to urge **NIDDK** to elevate liver research initiatives within their strategic plan

October

Annual **#OctoberIs4Livers** campaign

#BossesWearBurgundy campaign

Leadership in Liver Health Luncheon, October 6

Urged Congress to reintroduce the bicameral and bipartisan **LIVER Act (S. 3041 and H.R. 5675)**

Office of the CEO

Since our founding just over seven years ago, GLI has engaged in a range of advocacy activities to direct global attention to liver health commensurate with its prevalence and severity. During an auspicious November, **GLI and our CEO received two awards on behalf of the liver disease community in recognition of this impactful work.**

The **AASLD Distinguished Advocacy Service Award**, which recognizes sustained service to the hepatology community by raising awareness, garnering public and legislative support, and promoting liver health and patient care, was awarded to GLI during The Liver Meeting® Digital Experience on November 12.



AASLD Distinguished Advocacy Service Award

The **RARE Champions of Hope Founder's Award** — which our CEO Donna R. Cryer, JD, received just a week later on November 18 during the Global Genes RARE Health Equity Summit in Philadelphia, Pennsylvania — recognizes founders of impactful organizations in the rare disease community and acknowledges a commitment to *connecting, empowering, and inspiring* the community and advocating for people living with rare disease.

We are humbled and grateful to be the second annual awardee of each of these honors from longstanding, valued partners of GLI.



Rare Champions of Hope Founder's Award

Operations Updates

Throughout 2021, GLI invested significantly in upgrading the organization's technology and infrastructure and in increasing the team's level of liver health expertise: We transitioned to a new Customer Relations Management (CRM) platform, hired a professional accounting firm, prepared for our first full external audit, introduced a cloud-based project management system, created internal systems to increase efficiency and productivity in human resources, expanded the development team and structures, and prepared for international expansion with our legal team. The organization can expand upon this strong foundation to better serve the needs of the over **1.5 billion liver disease patients around the globe.**

Special Initiatives of the Office of the CEO



Throughout the year, GLI worked collaboratively with other organizations and committees in **advancing health equity practices** throughout the healthcare system



Diversity, Equity, & Belonging

Health equity is intrinsic to GLI's mission to *improve the lives of individuals and families impacted by liver disease*. We recognize the barriers created by longstanding, deeply embedded, systemic issues for liver patients in nearly all circumstances; however, these barriers disproportionately fall upon patients, families, and communities of color. COVID-19 has only magnified this disparity. Certain segments of the population suffer poorer health outcomes than others because of the contributing factors of *stigma, economic challenges, immigration status, biases in care delivery, inequity in access to digital technology, and disparate insurance coverage*. GLI believes in the importance of **diversity, equity, and belonging** in both our organization and our work. We are committed to creating structures and cultures that foster confidence and facilitate the engagement of the full and authentic individual.

Our policy agenda reflected our priority of health equity, such as in our support of:

The Medical Nutrition Equity Act (S. 2013 and H.R. 3783)

The Building COVID-19 Vaccine Confidence Act of 2021 (H.R. 1268)

The Improving Social Determinants of Health Act (S.104 and H.R. 379)

- CEO Donna R. Cryer spoke at *"Exploring Racial Differences and Disparities in PBC Care,"* a roundtable discussion to deepen understanding.



Exploring Racial Differences and Disparities in PBC Care webinar

- GLI helped **establish the future direction of diversity** in rare diseases as part of the steering committee that directs the Rare Disease Diversity Coalition.
- Involvement in *Global Genes' RARE Health Equity Leadership Council* allowed our leadership to amplify our principles and practices of diversity, equity, and belonging.
- GLI established its inaugural **Excellence in Health Equity award**, presented at the fall luncheon to the noteworthy team behind the Black Liver Health Initiative to spotlight their work addressing the historical and new barriers to liver care through engagement with the Black community.



From left to right: Julia Wattacheril, MD, MPH; Awardees Veronica Roye, DNP, FNP-BC, & Nicole Golden, DNP, FNP-BC; Donna R. Cryer, JD; & Rev. Thomas Bowen

Leadership in Liver Health Luncheon

In tandem with its annual #OctoberIs4Livers campaign, GLI hosted the first **Leadership in Liver Health Luncheon** at the Hay-Adams on October 6, 2021. The event raised the profile of crucial issues in liver health and showcased successes impacting the liver community. At the luncheon, GLI honored the team behind the Black Liver Health Initiative – Veronica Roye, DNP, FNP-BC; Nicole Golden, DNP, FNP-BC and Monica Nelson-Kone, BSN, RN – with the inaugural Excellence in Health Equity award.



COVID-19 Response Policy

GLI advocated throughout 2021 for the well-being of patients with liver disease in the midst of the COVID-19 pandemic. We successfully urged the Food and Drug Administration (FDA), the Centers for Disease Control and Prevention (CDC), and other government agencies to update their guidance and regulations to encourage additional COVID-19 vaccine doses for immunocompromised individuals. GLI promoted equity in COVID-19 vaccine distribution for vulnerable populations, both organ transplant recipients and communities of color.

Global Liver Institute
Response to
COVID-19
Pandemic for Liver
Patients and
Transplant Recipients

Communication

GLI continued to provide timely updates for patients with liver diseases through our **COVID-19 Response Program for Liver Patients**. As scientists, researchers, regulators, and the manufacturing supply chain worked to provide vaccinations, treatments, and PPE for society to combat COVID-19, we interpreted guidelines, provided recommendations, and demystified changes for immunocompromised patients, patients with liver diseases, and caregivers through regular educational posts shared on social media, as well as articles posted on our website and shared with our COVID-19 specific mailing list. In 2021, we published 8 COVID-19 articles.





European Office

Overview

GLI's European office is located in Rome, Italy, and facilitates our global partnerships by building relationships with the European Parliament and Commission and with prominent hepatology organizations around the world, such as: Asociación Latinoamericana para el Estudio del Hígado (ALEH), the Asian Pacific Association for the Study of the Liver (APASL), the European Association for the Study of the Liver (EASL), the European Liver and Intestine Transplant Association (ELITA), the European Reference Network for Hepatological Diseases (ERN RARE-LIVER), the Indian National Association for the Study of the Liver (INASL), the European Society for Paediatric

Gastroenterology Hepatology and Nutrition (ESPGHAN), the European Society for Organ Transplantation (ESOT), United European Gastroenterology (UEG), and the World Health Organization (WHO). In expanding our relationship beyond Europe, GLI's European Office has extended our capacity to interact with regional liver health organizations even further such as: the Canadian Liver Foundation (CLF), the European Cancer Patient Coalition (ECPC), Liver Patients International (LPI) and the PBC Foundation and has established GLI as a trusted partner for campaigns and events.

International #NASHDay

GLI has led International NASH Day since 2019. The WHO European Office for the prevention and control of Noncommunicable Diseases participated in #NASHDay for the first time with a video message underlining the importance of a global event that sheds light on NASH. In addition to AASLD and EASL, 17 of the major hepatology and scientific organizations throughout the world endorsed #NASHDay.



We are proud to collaborate with the WHO Regional Office for Europe. **Kremlin Wickramasinghe, MBBS, MSc, DPhil** from the European Office of the World Health Organization encourages a worldwide fight against obesity and NASH.

In 2021, GLI hosted our largest #NASHDay yet!

International #NASHDay AT A GLANCE



73

Countries



120

Partners



17

International
Endorsements




8

Virtual NASH
Educational Panels




73

International Speakers




11.5M

#NASHDay Impressions



4000

#NASHDay Posts




24

#NASHday Partner Videos



16


Brochures in
Languages



GLI President and CEO,
Donna R. Cryer, JD

Culinary Event

International NASH Day 2021 featured the first-ever culinary demonstration on liver-healthy cooking techniques and tips with **Celebrity Chef Daniel W. Thomas** and GLI President and CEO, **Donna R. Cryer, JD.**



NutriStyle App

During International NASH Day, GLI and NutriStyle Inc. announced a **personalized nutrition app for people living with liver disease, diabetes, and other chronic conditions or who want to maintain good liver health.**



Celebrity Chef
Daniel W. Thomas

International #NASHDay Impact

- GLI and its partners *EDUCATED* millions of people around the world about *NASH*.
- Organizations reached out to their *LOCAL COMMUNITIES*.
- Eight panels brought together leading experts in the *NASH* field to discuss treatment and care for patients with *NASH* and prevention strategies.
- Through the Virtual *NASH* Day Hill Day, *GLI* and advocates contacted many congressional offices in the U.S. House of Representatives and Senate to support the *LIVER Act*.

Read the 2021 NASH Day Report, watch the panels and download materials at NASH-day.com

NASH Programs

Overview


GLI's NASH Programs shine a spotlight on and coalesce a diverse coalition of stakeholders around the urgency of developing mechanisms for addressing the epidemic of NAFLD and NASH worldwide. The NASH Programs also include the Beyond the Biopsy campaign – dedicated to accelerating the acceptance and adoption of non-invasive diagnostics as an alternative to biopsy.



NASH Council

The NASH Programs convenes the NASH Council twice per calendar year and creates workgroups, materials, and campaigns to advance specific concepts and programs.


In 2021, the GLI NASH Council grew to over 80 member organizations and expanded its global reach, welcoming new member organizations and partners in pharmacology, diagnostics, and research; as well as medical societies, patient organizations, and NGOs.



U.S. NASH Action Plan Scorecard

The U.S. NASH Action Plan 2021 Scorecard, a year-end scorecard for the field of NAFLD and NASH, lists the accomplishments achieved according to the detailed agenda in the U.S. NASH Action Plan.

The scorecard is organized by each relevant stakeholder group – patients/carepartners, clinicians, medical societies, patient advocacy organizations, industry, payors, health systems, regulators, and policymakers. While gaps and challenges remain, tracking and acknowledging NASH successes according to the U.S. NASH Action Plan is pivotal for the field to respond on a national scale in 2022 and beyond.



Beyond the Biopsy

A multifaceted awareness campaign dedicated to accelerating the acceptance and adoption of non-invasive diagnostics as an alternative to liver biopsy.

The initiative encourages advocates to support greater adoption of non-invasive diagnostics by directly influencing legislative, regulatory, and coverage/reimbursement changes.

Check out the U.S. NASH Action Plan 2021 Scorecard at globalliver.org/wp-content/uploads/2022/06/2021USNASHActionPlanScorecard1.pdf



NASH Programs Impact



CLINICAL CARE OPTIONS®

NASH Core Curriculum

As part of the NASH Core Curriculum – an online resource center to improve clinician understanding of foundational concepts in NASH diagnosis, management, and emerging pharmacologic treatment strategies – NASH Programs created educational materials for the clinician and patient. *These materials, NAFLD-NASH 101: Resource for Patients and Caregivers and NAFLD-NASH 101: Resource for Clinicians, are available to supplement the NASH CME program created by GLI and Clinical Care Options, a NASH Council member.*




Surfing the NASH Tsunami Podcast:

Driving The Discussion In Fatty Liver Disease

In this weekly podcast, drug developers, investors, researchers, and corporate executives wrestle to understand what is happening in the commercial development of NASH medications. Roger Green, MBA, hosts the podcast, and GLI's President & CEO Donna R. Cryer, JD; GLI's Policy Director, Andrew Scott; and GLI's NASH Program Director, Jeff McIntyre, appear frequently as featured guests.

NASH Diagnostics Forum™

GLI's NASH Programs, in partnership with the Albert Einstein College of Medicine at the Montefiore Medical Center and NASH Council member Integritas Communications, convened the *NASH Diagnostics Forum™ – A Critical Appraisal of Non-Invasive Technologies in NASH: Informing the Future of NASH Diagnosis and Assessment*. **Nine experts in nonalcoholic steatohepatitis gathered to assess multiple components of the NAFLD/NASH diagnostic process with evidence to support or refute Clinical Assertion Statement on specific issues within NASH diagnostics.**



Advanced Advocacy Academy

Overview

Advanced Advocacy Academy (A3) is a year-round program dedicated to training patients and caregivers to be liver health advocates. A3 participants engage in liver health advocacy locally in their communities, federally in the U.S., and globally.

On September 21-23, 2021, GLI successfully held its **fifth annual Advanced Advocacy Academy**, a training program for liver patients, caregivers, and professionals seeking to elevate their advocacy knowledge and skills needed to advocate for liver health.

The virtual experience was constructed to introduce participants to a broad set of advocacy areas in which they could focus their future endeavors as effective patient advocates. These areas included media, storytelling, research and development, clinical trials, state and federal legislation, support, self care and more. A3 is the first step in GLI's on-going training and support for liver patients, caregivers, and support professionals, which provides them with the information, skills, and opportunities they need to effectively advocate for liver health.



The A3 Class of 2021 increased the total number of A3 participants, over the years, to over 200 from 36 U.S. states and 15 countries.

A3 2021 at a Glance

5

Continents

15

Countries

200

Advocates

36

U.S. States

16

Speakers

12

Hours of live online sessions and workshops



A3 Impact

- **Empowered** liver advocates to effectively champion the diverse needs and concerns of the liver patient community
- **Convened** a global cohort of liver health advocates to learn advocacy methods and identify intersections of needs and capabilities for patient and caregiver action
- **Instructed** hands-on media training to maximize impact of public speaking opportunities
- **Developed** guides and toolkits to support long-term success in liver health advocacy

Learn more about Advanced Advocacy Academy at www.globalliver.org/advanced-advocacy-academy

Selected **A3** Participant Quotes

“

...there is an **opportunity for everyone** to participate and that is the beauty of it. You can educate yourself at your own pace, you can talk to others and you can grow...



Lorrinda Davis

“

...I think A3 is what finally allowed me to feel comfortable adding **patient advocate** after my name; beforehand I would say it, but I felt like I didn't really know what I was doing...I think (after) coming to A3, now I'm very comfortable typing it out: John Mahalchak, Patient Advocate



John Mahalchak

Liver Cancers Program

Overview

Liver cancer is one of the few cancer types with increasing incidence and mortality rates, with the World Health Organization reporting an estimate of **905,677 new cases** and **830,180 deaths** from liver cancer globally in 2020. This devastating disease disproportionately impacts marginalized racial and ethnic groups in the US and globally. GLI strives to bring awareness, education, and policy changes to the liver cancer community by amplifying the voices of those impacted. The Liver Cancers Program has fostered multidisciplinary collaborations to accomplish this aim as guided by the Liver Cancers Council with the annual #OctoberIs4Livers campaign and the educational website Liver Central.




Liver Cancers Council

With **more than 30 members**, GLI's Liver Cancers Council brings together committed stakeholders across the liver cancer community to share expertise and direction about programs and initiatives addressing all aspects of the liver cancer continuum. The council consists of international patient advocacy organizations, individual healthcare professionals, medical societies, and corporate partners.

#OctoberIs4Livers

Each October, GLI leads #OctoberIs4Livers, the first and only global program dedicated to public awareness, policy, and clinical practice needs to prevent and manage liver cancers. Throughout the month of October, patients, survivors, healthcare providers, medical associations, patient-based organizations, government agencies, community partners and the industry come together to elevate the dialogue about liver cancers and collaborate to improve liver cancer outcomes.



#Octoberis4Livers at a Glance



Press Release
Potential Reach

282,409,604



Estimated
Program Reach

288,342,841



Social Media Analytics:



Social Media
Impressions

5,165,442



Engagements

2,961,681



Program Growth Rate
since 2020

190 %

Liver Central

In the fourth quarter of 2021, GLI launched **Liver Central**. This new and innovative website was created to serve as a comprehensive online guide for all things related to liver cancer– both primary and secondary liver cancers. The content on the site was carefully curated to provide valuable information and links to current and relevant research addressing **liver cancer**. The site is structured to meet the needs of different online audiences including *new patients*, *experienced patients*, and *clinicians* and *researchers*.

Check out *Liver Central* at livercentral.org

Liver Cancers Program Impact

- **ELEVATED** the global dialogue about liver cancer through a bolstered **#OctoberIs4Livers** education and awareness program
- **CONVENED** global leaders in liver cancer within the **Liver Cancers Council** to improve the lives of liver patients
- **DEVELOPED** the first **State of Liver Cancer Report and accompanying U.S. Congressional briefing** to provide up-to-date analysis and inform decision-makers about the burden of liver cancer and path towards equity in care
- **RAISED** the profile of liver health and honored important equity work in liver care through the inaugural Global Liver Institute **Leadership in Liver Health Luncheon**
- **EXECUTED** a social media campaign entitled **#BossesWearBurgundy** in which high-profile participants shared photos wearing burgundy to support liver health



Pediatric and Rare Liver Diseases Programs

Overview

2021, despite being a particularly challenging year for so many, was a year of growth and solidification within the Pediatric and Rare team. The Pediatric and Rare team doubled in size, with a program manager and a director – both with lived experience in rare liver diseases – working together to maximize potential outreach of the Council.

The department, along with GLI, extended our reach by joining Liver Patients International (LPI), an umbrella organization consisting of many national and international liver patient organizations, with our P&R director being voted in as Vice-Chair of LPI.



Pediatric and Rare Liver Diseases Council

The Pediatric and Rare Liver Diseases Council is a global multi-stakeholder collective of leaders within the pediatric and rare liver disease communities.

The council assembles to share an important mix of knowledge, ideas and best practices from patients and patient organizations, clinicians with a special interest, policymakers, and pharmaceutical industry partners. In 2021, the Council included **35 organizations from 8 countries**. The Council has a series of working groups with particular specializations – Research, Education, Policy, and International Classification of Diseases 10th Revision (ICD-10) – within the pediatric and rare space. Projects include ICD-10 code nominations, educational brochures, landscape analysis, and more.

Inaugural Rare Liver Diseases Month & #RareAware Campaign

The Pediatric and Rare Liver Diseases team led its **first Rare Liver Diseases Month campaign** to bring needed attention to the over 100 little-known liver diseases and increase support for these patients around the globe. To achieve these goals, the team prepared an **advocate toolkit** and resource and **fact sheets** with registries and organizations and also highlighted rare diseases on GLI LIVE, our weekly educational interview show.



Social Media Campaign Impressions

837,130




Press Release Potential Reach

981,421,517



Press Release Placements

50



Please visit globalliver.org/rare for more information about the work of the Pediatric and Rare Liver Diseases team.



Liver Health Policy



Take action today: www.globalliver.org/take-action

Overview




In 2021, Global Liver Institute worked at the **national** and **global** level to actively shape public policy through:

ENCOURAGING collaboration across sectors

Collectively **IMPLEMENTING** legislative and regulatory approaches that are patient centric

ELEVATING liver health holistically

ADVANCING community goals and initiatives specific to liver health simultaneously



GLI's Policy Department created opportunities for liver advocates and Liver Action Network organizations to show the groundswell of support for liver health policy through multiple Virtual Advocacy Days as part of International NASH Day and A3.

GLI-led liver advocacy days included more than **100 liver advocates** and met more than **80 Congressional Offices** representing more than **40 states**.



GLI's Policy Department worked collaboratively with regulators, research agencies, and public health departments

on a variety of initiatives with the goal of urging a great recognition of the unique perspective and ability of patients to contribute to the understanding of their condition and treatment management.



2021 Policy Impact

- Successfully elevated liver health within 7 U.S. Federal Agencies and Task Forces and:
- Prioritized **COVID-19 VACCINE** doses for immunocompromised individuals
- Elevated **LIVER RESEARCH** initiatives
- Included NASH in the conversation with type 2 diabetes screening, and treatment
- Highlighted **LIVER CANCER AWARENESS MONTH** and released a **LIVER CANCER** statement
- Worked on the first **NASH** Externally- Led Patient-Focused Drug Development meeting



GLI encouraged bipartisan, bicameral collaboration and the development of patient-centric legislative packages through:

- **PROMOTING REFORM OF THE ORGAN TRANSPLANTATION SYSTEM**
- **REINTRODUCING A BILL THAT PRIORITIZES THE LIVER**, the LIVER Act (S. 3041 and H.R. 5675)
- **INTRODUCING THE FIRST OCTOBER IS LIVER CANCER AWARENESS MONTH RESOLUTION**
- Collaborating on the eventual reintroduction of the **NASH** Care Act
- Leading Congressional Briefings on **NASH** and the State of Liver Cancer
- Advancing the expansion of liver public health programs to address issues such as viral hepatitis



Liver Action Network

To meet the needs of a rapidly growing cadre of liver health advocates, capitalize on the eagerness of patients and physicians to be active, and address the needs and opportunities of the community, GLI launched the Liver Action Network (LAN) in May 2021.

Representing more than 40 U.S. states, 2 countries, and 11 community liver advocacy organizations, the LAN is a first-of-its-kind network that provides community member organizations a central structure for the formulation of collective policy positions and programmatic solutions.

LAN member organizations are provided opportunities to use their voices and insights from lived experiences to advance liver health initiatives at local, state, national, and international levels through legislative, regulatory or coverage/ reimbursement changes on behalf of all people at risk for or living with liver conditions.

Join our Liver Action Network: globalliver.salsalabs.org/signuptoday/

NASH EL-PFDD

In November, GLI coordinated an **externally-led Patient-Focused Drug Development (EL-PFDD)** meeting about NASH. This meeting brought patient stories and perspectives about NASH and the drug development process to the attention of policymakers and other stakeholders in the field. Many LAN members participated as patient panelists.

“

I was diagnosed with metabolic syndrome many years ago before starting my liver journey which started with the bruises... but was never told that this could lead to liver disease.

Bruce Dimmig
Patient Advocate
at EL-PFDD meeting

“

Patients and providers need to urgently know that (a NASH diagnosis) is the beginning of a progressive serious disease and they need to stop it.

Suzanne Maisner
Patient Advocate
at EL-PFDD meeting



Communications

Overview

GLI's Communications Department amplifies the impact of GLI's programs and facilitates the flow of information between GLI and the public through GLI's website, social media channels, campaigns, press releases, and more. The department builds and maintains strong personal connections to the patients we serve and their caregivers and families. Additionally, the department maintains relationships with physicians, partners, media, and professionals in the liver health field to raise liver health to its rightful place on the global public health agenda.

Websites

GLI's websites, GlobalLiver.org and NASHday.com are the ultimate destinations for liver health resources, GLI updates, and world news affecting the liver health community. In November 2021, GLI launched Liver Central, a hub for all things liver cancer to meet the needs of new patients, experienced patients, and clinicians.

Press Releases

As GLI continued to take newsworthy action and launch notable initiatives, its press releases were picked up by many outlets including Yahoo Finance and Yahoo News. From January 2021 to December 2021, GLI sent out 6 press releases on the newswire, reaching millions of readers in the U.S., Canada, and around the world.

Newsletters

GLI continued to send out two monthly newsletters along with its special edition COVID-19 updates to a robust list of subscribers. GLI's newsletters consistently receive high open and click rates, exceeding the averages for nonprofit organizations.

Social Media

Throughout 2021, GLI's Communications team supported numerous internal and external campaigns. The team **strategized, designed, executed, and monitored** GLI's main internal campaigns.



Pediatric and Rare Liver Diseases' #RareAware campaign, throughout the month of February



International NASH Day on June 10



Liver Cancers #OctoberIs4Livers campaign, throughout the month of October



GLI President and CEO,
Donna R. Cryer, JD

#BossesWearBurgundy throughout the month of October

To honor the millions of people worldwide living with liver disease and spread awareness of these conditions, GLI led a social media campaign entitled **#BossesWearBurgundy**. Journalists, congressional representatives, health care providers, patient advocates, and others showed their support by posting a picture wearing burgundy and inviting others to join the challenge. (see page 53 for full list of participants)



Kingman Regional Medical
CenterKingman, AZ



Bakari Sellers, Political
Analyst, CNN



Rep. James E. Clyburn, Majority Whip, U.S.
House of Representatives (D-SC)



Margaret Hoover, Host of Firing Line, PBS
Political Commentator, CNN



GLI uses **social media** as a tool to disseminate educational material and join global conversations about liver health with patients, physicians, policymakers, partner organizations, and experts in the field to continuously elevate liver health.



DOUBLED our LinkedIn audience



INCREASED TWITTER FOLLOWING BY ~25%



Hosted live streams and engaged strong audience on Facebook



RE-ESTABLISHED a robust and continuous Instagram presence



CONTINUED TO GROW our repository of liver health educational content on our YouTube channel



GLI LIVE

Launched in 2020 as part of our comprehensive COVID-19 response program for liver patients, GLI LIVE provides an outlet to increase connectivity among the liver community through engaging conversation and discussion on a variety of timely topics. Throughout 2021, Donna Cryer, GLI Founder and CEO, continued to host weekly episodes featuring lively dialogue and interesting perspectives from expert guests. Ranging from Members of Congress to physicians, key opinion leaders in the liver health field, liver cancer survivors, and even performers from Broadway's Hamilton, guests on GLI LIVE provide rich new information and key perspectives relevant to the liver health of individuals, communities, and nations. The show has expanded beyond its origins to cover timely topics across the breadth of the liver health field that align with both GLI and external campaigns. (see full list of episodes and guests on page 54)



2020 External Audit Results

The show streams live every Wednesday at 12 pm ET on **Facebook, YouTube, and Twitter.**

IN 2021, GLI HOSTED **37** EPISODES OF GLI LIVE



GLI LIVE with Ned Sharpless, MD, Director of the National Cancer Institute of the United States



GLI LIVE with Dr. Martha Dawson, Associate Professor at University of Alabama at Birmingham and President of the National Black Nurses Association

INDEPENDENT AUDITOR'S REPORT

To the Board of Directors of
Global Liver Institute, Inc.
Washington, D.C.

Report on the Financial Statements

We have audited the accompanying statement of financial position of **Global Liver Institute, Inc.** (a non-profit organization) as of December 31, 2020, and the related notes.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of this financial statement in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on this financial statement based on our audit. We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statement is free of material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statement. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statement, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial statement in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting principles used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statement.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

INDEPENDENT AUDITORS' REPORT (Continued)

To the Board of Directors of
Global Liver Institute, Inc.
Washington, D.C.

Opinion on the Statement of Financial Position

In our opinion, the statement of financial position referred to above presents fairly, in all material respects, the financial position of **Global Liver Institute, Inc.** as of December 31, 2020 in accordance with accounting principles generally accepted in the United States of America.

Disclaimer of Opinion on Statements of Activities, Functional Expenses, and Cash Flows

Because we were not engaged to audit the statements of activities, functional expenses, and cash flows, we did not extend our auditing procedures to enable us to express an opinion on results of operations and cash flows for the year ended December 31, 2020. Accordingly, we express no opinion on the statement of activities, functional expenses, and cash flows for the year ended December 31, 2020.

Jedon Foster of Cryder, P.A.

Rockville, Maryland
March 8, 2022



Thought Leadership: CEO Speaking Engagements



WEEKLY HOST GLI LIVE

RECURRING GUEST

Surfing the NASH Tsunami Podcast

JANUARY 13

Moderated National Health Council CEO Affinity Group discussion on **insights from**

Pfizer on the COVID-19 vaccine rollout

JANUARY 14

Global Genes & Biotech Showcase - RARE Beyond the Square - Speaker

JANUARY 27

Roche's Global HCC Network - Global Patient Representative

FEBRUARY 2

Veterans Administration Extension for Community Healthcare Outcomes - Hepatology Conference – The Fierce Urgency of Now: How the VA is Uniquely Equipped to Lead in Addressing the Challenges of NASH and Why It Must - Speaker

FEBRUARY 10

Physician's Weekly Podcast - Response to FDA Briefing on NASH Drug Development - Speaker

FEBRUARY 11

Weinstein Carnegie Philanthropic Group - Social Impact Power Hour on Clubhouse - Rare Diseases and Getting More Awareness for Them - Speaker

FEBRUARY 16

Health Datapalooza & National Health Policy Conference - Chicken Little, the Sky Is (NOT) Falling: Addressing Fears about Patient Access to Health Data - Speaker

MARCH 19


South by Southwest (SXSW) - Bristol Myers Squibb - Healthcare Amid COVID: Virtual Support & Advocacy – Panelist

MARCH 19

Office of the National Coordinator for Health Information Technology (ONC) - A Policy & Technology Workshop on Write-Back APIs – Speaker

MAY 4

House Oversight Committee - Organ Procurement Inquiry Testimony - Speaker



MAY 6

ISPOR Patient Representatives Roundtable - Speaker

MAY 12

Genfit - American Diabetes Association TV Interview - NASH, T2DM, and Patient Identification/Management - Speaker

MAY 18

Research!America - Diversity in Clinical Trials Roundtable - Speaker

MAY 20

National Capital Region - Association of Corporate Counsel (NCR/ACC) Non-Profit Conference - Overseeing Organizational Culture: If Governance isn't Part of the Solution, It's Part of the Problem - Speaker

MAY 21

American Board of Internal Medicine - Brain Trust Launch - Speaker



JUNE 2

Managed Healthcare Executive - FDA Oncologic Drugs Advisory Committee - Speaker

JUNE 3

The Post and Courier Newspaper - Organ Procurement - Interview

JUNE 11

Global Genes - Rare Drug Development Symposium - Seizing the Moment: Expanding Impact and Access in Translational Science - Moderator

JUNE 15

Mission: Readiness Podcast - Liver Health Episode - Speaker

JUNE 17

Bayer - LinkedIn Live - The new healthcare intelligence: How digitalization empowers people to manage their health - Panelist



JUNE 23

HepDynamics - Digital International Liver Congress 2021 - What Patients and Advocates Can Expect - Interview

JUNE 25

Biotechnology Innovation Organization (BIO) - CT Diversity Summit - The Imperative of Community & Patient Engagement: Building Trust in & Awareness of Opportunities to Participate in Clinical Trials - Opening Remarks + Moderator



JUNE 30

Drug Information Association (DIA) - Global Annual Meeting - The Intersection of Health Equity and Personalized Medicine - Speaker

JULY 12

HepDynamics - Surfing the NASH Tsunami - Optimizing Trial Recruitment by Broadening our Field of Vision - Host

JULY 15

WCG Clinical - Interview with Global Liver Institute - Speaker

JULY 20

Genentech - National Medical Association 2021 - Driving for health equity through early screening - Speaker

AUGUST 12

Proceedings of the National Academy of Sciences - Rise of decentralized, virtual clinical trials in the wake of the Covid-19 pandemic - Interview

AUGUST 19

Axdev Group - Study in the Field of NAFLD, NASH, and Advanced Fibrosis - Interviewee

AUGUST 23

Novartis - Expert Patient PRO Advisory Board - Reviewer

SEPTEMBER 3

Horizon Therapeutics & MIT Solve - The Horizon Prize - Judge

SEPTEMBER 17

National Committee for Quality Assurance (NCQA) - NASH Roundtable - Improving Quality of Care for Nonalcoholic Steatohepatitis (NASH) Disease - Panelist

SEPTEMBER 28

Global Genes - RARE Patient Advocacy Summit - From Awareness to Participation: Bridging Gaps in Representation in Research - Speaker

OCTOBER 22

Sanofi - Global Liver Forum (GLF) Webinar - Efforts for Early Detection and Screening of NAFLD, and Global Burden of NAFLD - Speaker

NOVEMBER 14

AASLD - The Liver Meeting - Grit, Grace, Gratitude & Resilience: What You Wish Your Doctors Knew About You - Speaker

NOVEMBER 17

Healthy Churches 2030 Annual Conference - Demanding a Seat at the Clinical Trials Table: Why Inclusion Matters! - Panelist

Financial Overview

Assets

Cash and Cash Equivalents	\$	154,409
Accounts Receivable		135,810
Other Current Assets		22,645
Fixed Assets-Net		17,190
Other Assets		—
Total Assets		330,054

Liabilities and Net Assets

A/P and accrued expenses		294,165
Deferred Revenue		470,568
Loan Payable - PPP loan		—
Total Liabilities		764,733
Net Assets Total		434,679
Liabilities and Net Assets		330,054

Revenue


Memberships		758,207
Contributions-Unrestricted		332,263
Contributions-Restricted		229,000
Sponsorships		482,000
Other Revenues		41,231
Gain on Debt Extinguishment-PPPL		64,880
Total Revenue		1,907,581

Expenses


Programs and Grants		1,821,739
General and Administrative		543,105
Fundraising		58,177
Total Expenses		2,423,022

CHANGE IN NET ASSETS	\$	515,441
NET ASSETS, BEGINNING OF YEAR		80,763
NET ASSETS, END OF YEAR		434,679

GLI Revenue Types



Expenses by Program



Appendix

#BossesWearBurgundy participants

Cecilia Abbot	First Lady of Texas
Andrea Michelle Alexander	Chief People Officer, Rent the Runway
Steve Benjamin	Mayor of Columbia, South Carolina
Michael Betel	President & Founder, Fatty Liver Alliance
Diane Brockmeier	President and CEO, Mid-America Transplant
Katie Brown	Cancer Survivor, Writer, & Patient Advocate
Rep Tony Cardenas	Member, U.S. House of Representatives (D-CA)
James E. Clyburn	Majority Whip, U.S. House of Representatives (D-SC)
Jenn Jones	Representatives (D-SC)
Teri P. Cox	Patient Advocate
Mario Diaz-Balart	President, Cox Communication Partners
Rep. Jeff Duncan	Member, U.S. House of Representatives (R-FL)
Senator Bill Frist, M.D.	Member, U.S. House of Representatives (R-SC) Former Majority Leader, United States Senate Heart Transplant Surgeon
Kristine Gauvreau Urea	Executive Vice President, Market Performance Group
Lt. Gov. Adam Gregg	Iowa's 47th Lieutenant Governor
Margaret Hoover	Host of Firing Line, PBS Political Commentator, CNN
Charisse Hughes	SVP & Global CMO at Kellogg Company
Dr. Jackie Kassouf Maalouf	President & Founder, National Diabetes Organization - DiaLeb
Robin Kelly	Member, U.S. House of Representatives (D-IL)
Monica McGurk	Chief Global Growth Officer, Kellogg
Raquel Peck	Founder & Director, Clarion I. Former CEO, World Hepatitis Alliance
Eva Pilgrim	Co-Anchor, Good Morning America Correspondent, ABC News
Bill Remak	Chair of the Board of Directors/CEO, California Hepatitis C Taskforce
Tony Sanneh	American retired professional soccer player
Bakari Sellers	Political Analyst, CNN
Parul Sood	Deputy General Manager Marketing, Zydus Group - Hepatology & Gastroenterology

Institutions

Kingman Regional Medical Center, Kingman, AZ

Mental Illness Recovery Center, Inc. (MIRCI), Columbia, SC

TriSalus Life Sciences, Westminster, CO

GLI LIVE episodes and guests

European Liver Research, Education, and Policy

Prof. Thomas Berg, Head Division of Hepatology, University Medical Center Leipzig, Germany and Secretary General, European Association for the Study of the Liver (EASL)

Liver Health Policy in 2021

Tamar Taddei, MD, leader of the AASLD Public Policy Committee

Dry January

Chris Boyd, co-founder of Drink Monday

Rare Disease Month: Lysosomal Acid Lipase Deficiency (LAL-D)

Don P. Wilson, MD, Pediatric Endocrinologist, Cook Children's Medical Center and Secretary of Foundation of the National Lipid Association

Rebecca Trendy, mother of four boys living with lysosomal acid lipase deficiency (LAL-D)

Rare Disease Month: Alagille Syndrome

Cher Bork, Executive Director of Alagille Syndrome Alliance

Shambhavi Ravishankar, Alagille syndrome patient, ALGSA board member, attorney

Rare Disease Month: Primary Sclerosing Cholangitis (PSC)

Marco Carbone, MD, Hepatologist, University of Milan-Bicocca, European Reference Network (ERN)'s clinical lead for cholestatic liver diseases

Cynthia Bunes, mother of a Primary Sclerosing Cholangitis (PSC) patient,

Rare Disease Month: Primary Biliary Cholangitis (PBC)

Cynthia Levy, MD, Hepatologist, Associate Director, Schiff Center for Liver Diseases, University of Miami

Leslie Stratta, patient advocate, living with PBC

The Connection Between Liver Health and Kidney Health

Richard Knight, President, American Association of Kidney Patients

NASH, Obesity, and Liver Health

Rotonya Carr, MD, FACP, Associate Professor of Medicine, Hospital of the University of Pennsylvania

Policy Partners: Advocating for Liver and Kidney Health

Rachel Meyer, Senior Director of Policy and Government Affairs, American Society of Nephrology

David White, Regulatory and Quality Officer, American Society of Nephrology

Zachary Kribs, Senior Government Affairs Specialist, American Society of Nephrology

Andrew Scott, Director, Policy, Global Liver Institute

Why Weight Can't Wait

William Dietz, MD, Director, Sumner M. Redstone Global Center for Prevention and Wellness, Milken Institute School of Public Health, George Washington University and Director, STOP Obesity Alliance, The George Washington University

Overcoming Weight Bias and Stigma

Joe Nadglowski, President & CEO, Obesity Action Coalition

Through the Lens of Kidney Health: Advocacy in Action

Troy Zimmerman, Special Projects Director, National Kidney Foundation

Constructing a more Equitable Kidney Health Agenda

LaVarne Burton, President & CEO, American Kidney Fund

Stories of Tragedy & Triumph

Ms. Delores Benton Evans, Donor Mother

Dara Kass, MD, Emergency Medicine Physician & Founder of FemInEM

The Evolution of COVID-19 Response: Looking Back & Moving Forward

Martha A. Dawson, DNP, RN, FACHE, President, National Black Nurses Association

GI Cancer Research and Patient Advocacy

Mark Lewis, MD, Director, Gastrointestinal Oncology, Intermountain Healthcare

Physical Activity and NASH

Jonathan Stine, MD, MSc, FACP, Director of Research, Penn State Liver Center

Hepatitis Testing Day

Su Wang, MD, MPH, President, World Hepatitis Alliance

Patients Changing the Conversation on Liver Disease

Kendall Ciesemier, NGO Founder, Writer, Reporter
Nora Logan, Writer, Patient Advocate

Liver Action Network Launch

Scott Suckow, Liver Coalition of San Diego
Farrah Douglas, Liver Wellness Foundation
Teresa Davidson, Mid-South Liver Alliance

Setting the Global NASH Agenda in NASH

Prof Jeff Lazarus, EASL's International Liver Foundation
Vice-Chair

Every liver, every time: Best Practices in Organ Donation and Recovery

Diane Brockmeier, President & CEO,
Mid-America Transplant
Kevin Lee, Chief Organ Operations, Mid-America Transplant

Liver Healthy Eating: There's an App for That

Todd Albro, Co-Founder ^ CEO, NutriStyle Inc.
Scott Murdoch, PhD, RD, Co-Founder & CNP,
NutriStyle Inc.

Self-care Summer: A Chance to Reset and Refresh

Donna R. Cryer, President & CEO, Global Liver Institute

World Hepatitis Day

Michael Ninburg, Executive Director, Hepatitis
Education Project

What Should Transplant Recipients Know About COVID-19

Dr. Deepali Kumar, President-Elect, American Society
of Transplantation

Meet the A3 Advocates

Lorrinda Gary Davis, Founder & President,
Trio-Oklahoma Organization
John Mahalchak, Patient advocate

Transplant Survivorship

Warren Maley, MD, Director, Jefferson Transplant Institute
Nicole Wells, Transplant Recipient, Pediatric & Rare Liver
Diseases Program Manager, Global Liver Institute

The National Cancer Act at 50 & the Prospects for Ending Liver Cancer

Dr. Norman E. Sharpless, Director, National Cancer Institute

Cancer Advocacy and Patient Support #OctoberIs4Livers

Matthew Zachary, Advocate, Podcast Hero, Founder
of OffScrip Media & Stupid Cancer

Addressing Liver Cancer Disparities in the American Indian & Alaska Native Communities #OctoberIs4Livers

Behnoush Momin, DrPH, MS, MPH, Health Scientist,
Center for Disease Control
Stephanie Melkonian, PhD, Epidemiologist, Center
for Disease Control

Breakthrough Treatment Options in Liver Cancer #OctoberIs4Livers

Dr. Maria Reig, Head of Barcelona Clinic Liver Cancer
(BCLC Group)

Booster Shots & COVID-19 Updates

Robert Fontana, MD, FAASLD, Professor of Internal
Medicine, Medical Director of Liver Transplantation

Liver Health & National Security - A Tribute to Veterans Day

Major General (Ret.) Michael S. Hall, U.S. Air Force

NAFLD, NASH & Diabetes

Brent Tetri, MD, Gastroenterology, Internal Medicine,
Hepatology, SLUcare Missouri

GLI LIVE meets NASH Tsunami

Roger Green, Roger Green, Managing Principal - HEP
Dynamics, Executive Producer & Host of Surfing
the NASH Tsunami

Introducing Liver Central

Steven Katz, MD, FACS, Chief MEical Officer, TriSalus
Life Sciences

Picking up Where we Left off

Ekaterina (Katy) Samli, MPA, MPH, PMP, Project Manager,
Integrated Care, Motefiore Care Management

 globalliver.org
 info@globalliver.org
 [@globalliverinstitute](https://www.instagram.com/globalliverinstitute)
 [@GlobalLiver](https://www.facebook.com/GlobalLiver)
 [Global Liver Institute](https://www.linkedin.com/company/global-liver-institute)



globalliver.org

Info@globalliver.org

(800) 845-5910

4323 Westover Place, NW Washington, DC 20016

Donate Today!



*We put your
contribution to work!*



Global Liver Institute (GLI) is a patient-driven 501(c)3 nonprofit organization headquartered in Washington, DC, with offices in the EU and UK, founded in the belief that liver health must take its place on the global public health agenda commensurate with the prevalence and impact of liver disease and the importance of liver health to well-being. GLI promotes innovation, encourages collaboration, and supports the scaling of optimal approaches to improve research, care, and policy. By bringing together more than 200 community-based, national, and international organizations across its Councils, Campaigns, and events, GLI equips advocates to identify and solve the problems that matter to liver patients. Follow GLI on Twitter, Facebook, Instagram, LinkedIn, and YouTube.